Duygu Ozaskın

Afyonkarahisar, 03030, Turkey

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Palliative Care Awareness Among Caregivers of Cancer Patients in Turkey: A Cross-Sectional Study.

Palliative Care Awareness Among Caregivers of Cancer Patients in Turkey: A Cross-Sectional Study.

Journal: Current oncology (Toronto, Ont.)
Published: June 16, 2026

Aprepitant and Fosaprepitant for Preventing Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy-A Real-World Study.

Aprepitant and Fosaprepitant for Preventing Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy-A Real-World Study.

Journal: Current oncology (Toronto, Ont.)
Published: May 13, 2026

The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study.

The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study.

Journal: Medicina (Kaunas, Lithuania)
Published: February 22, 2026

Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab.

Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab.

Journal: Scientific reports
Published: February 01, 2026

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: November 14, 2025

Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study.

Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study.

Journal: International journal of cancer
Published: August 13, 2025

Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study.

Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study.

Journal: Discover oncology
Published: April 30, 2025

Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study.

Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study.

Journal: Journal of chemotherapy (Florence, Italy)
Published: March 18, 2024

Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study.

Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study.

Journal: Breast cancer research and treatment
Published: March 17, 2024

Comparison of clinicopathological and prognostic features of breast cancer patients younger than 40 years and older than 65 years.

Comparison of clinicopathological and prognostic features of breast cancer patients younger than 40 years and older than 65 years.

Journal: Discover oncology
Published: December 07, 2023
Showing 1-10 of 10

Last Updated: 09/26/2026